Prognostic value of serum MMP-8, -9 and TIMP-1 in patients with hepatocellular carcinoma

Annals of Medicine

Volumn 45, Issue 7, 2013, Pages 482-487

  Lempinen, Marko ^a   Lyytinen, Ilaana ^a   Nordin, Arno ^a   Tervahartiala, Taina ^a   Makisalo, Heikki ^a   Sorsa, Timo ^a   Isoniemi, Helena ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

HCC; MMP; tumor markers

Indexed keywords

ALCOHOL; ALPHA FETOPROTEIN; BILIRUBIN; COLLAGENASE 3; GELATINASE B; NEUTROPHIL COLLAGENASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ADOLESCENT; ADULT; AGED; ALPHA FETOPROTEIN BLOOD LEVEL; ARTICLE; BILIRUBIN BLOOD LEVEL; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURGERY; CANCER SURVIVAL; CHEMOEMBOLIZATION; COHORT ANALYSIS; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE SPECIFIC SURVIVAL; ENZYME BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLUOROMETRY; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOFLUORESCENCE TEST; IMMUNOFLUOROMETRY; LIVER CELL CARCINOMA; LIVER RESECTION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MULTIMODALITY CANCER THERAPY; OVERALL SURVIVAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; THERMOABLATION; TUMOR ABLATION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, HEPATOCELLULAR; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FINLAND; FLUOROIMMUNOASSAY; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; MALE; MATRIX METALLOPROTEINASE 8; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; TIME FACTORS; TISSUE INHIBITOR OF METALLOPROTEINASE-1; YOUNG ADULT;

EID: 84885666393     PISSN: 07853890     EISSN: 13652060     Source Type: Journal    
DOI: 10.3109/07853890.2013.823779     Document Type: Article

References (59)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008 : GLOBOCAN 2008. Int J Cancer. 2010; 127: 2893-917.
2. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011; 61: 69-90.
3. Llovet JM, Fuster J, Bruix J. The Barcelona approach: diagnosis, staging, and treatment of hepatocellular carcinoma. Liver Transpl. 2004; 10(2 Suppl 1) : S115-20.
4. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet. 2003; 362 : 1907-17.
5. Llovet JM, Fuster J, Bruix J. Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology. 1999; 30: 1434-40.
6. Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet. 2012; 379 : 1245-55.
7. Poon RT, Fan ST, Ng IO, Lo CM, Liu CL, Wong J. Diff erent risk factors and prognosis for early and late intrahepatic recurrence aft er resection of hepatocellular carcinoma. Cancer. 2000; 89: 500-7.
8. Fukuda S, Itamoto T, Nakahara H, Kohashi T, Ohdan H, Hino H, et al. Clinicopathologic features and prognostic factors of resected solitary small-sized hepatocellular carcinoma. Hepatogastroenterology. 2005; 52 : 1163-7.
9. B efeler A S, D i Bisceglie A M. H epatocellular carcinoma: diagnosis and treatment. Gastroenterology. 2002; 122: 1609-19.
10. B ehne T, C opur M S. B iomarkers for hepatocellular carcinoma. I nt J Hepatol. 2012; 2012: 859076.
11. Lopez-Otin C, Bond JS. Proteases: multifunctional enzymes in life and disease. J Biol Chem. 2008; 283: 30433-7.
12. O kazaki I, N abeshima K. I ntroduction: MMPs, ADAMs/ADAMTSs research products to achieve big dream. Anti-Cancer Agents Med Chem. 2012; 12 : 688-706.
13. Sorsa T, Tjaderhane L, Konttinen YT, Lauhio A, Salo T, Lee HM, et al. Matrix metalloproteinases: contribution to pathogenesis, diagnosis and treatment of periodontal infl ammation. Ann Med. 2006; 38: 306-21.
14. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer. 2002; 2: 161-74.
15. Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res. 2003; 92 : 827-39.
16. Brew K, Dinakarpandian D, Nagase H. Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochim Biophys Acta. 2000; 1477 : 267-83.
17. Chirco R, Liu XW, Jung KK, Kim HR. Novel functions of TIMPs in cell signaling. Cancer Metastasis Rev. 2006; 25: 99-113.
18. Maatta M, Soini Y, Liakka A, Autio-Harmainen H. Diff erential expression of matrix metalloproteinase (MMP)-2, MMP-9, and membrane type 1-MMP in hepatocellular and pancreatic adenocarcinoma: implications for tumor progression and clinical prognosis. Clin Cancer Res. 2000; 6 : 2726-34.
19. Zhang Q, Chen X, Zhou J, Zhang L, Zhao Q, Chen G, et al. CD147, MMP-2, MMP-9 and MVD-CD34 are signifi cant predictors of recurrence aft er liver transplantation in hepatocellular carcinoma patients. Cancer Biol Th er. 2006; 5: 808-14.
20. Altadill A, Rodriguez M, Gonzalez LO, Junquera S, Corte MD, Gonzalez-Dieguez ML, et al. Liver expression of matrix metalloproteases and their inhibitors in hepatocellular carcinoma. Dig Liver Dis. 2009; 41 : 740-8.
21. Chen R, Cui J, Xu C, Xue T, Guo K, Gao D, et al. The signifi cance of MMP-9 over MMP-2 in HCC invasiveness and recurrence of hepatocellular carcinoma aft er curative resection. Ann Surg Oncol. 2012; 19(Suppl 3) : S375-84.
22. Makitalo L, Rintamaki H, Tervahartiala T, Sorsa T, Kolho KL. Serum MMPs 7-9 and their inhibitors during glucocorticoid and anti-TNFalpha therapy in pediatric infl ammatory bowel disease. Scand J Gastroenterol. 2012; 47: 785-94.
23. Pradhan-Palikhe P, Vikatmaa P, Lajunen T, Palikhe A, Lepantalo M, Tervahartiala T, et al. Elevated MMP-8 and decreased myeloperoxidase concentrations associate signifi cantly with the risk for peripheral atherosclerosis disease and abdominal aortic aneurysm. Scand J Immunol. 2010; 72 : 150-7.
24. Pussinen PJ, Sarna S, Puolakkainen M, Ohlin H, Sorsa T, Pesonen E. The balance of serum matrix metalloproteinase-8 and its tissue inhibitor in acute coronary syndrome and its recurrence. Int J Cardiol. 2013; 167 : 362-8.
25. Suonpaa MU, Lavi JT, Hemmila IA, Lovgren TN. A new sensitive assay of human alpha-fetoprotein using time-resolved fl uorescence and monoclonal antibodies. Clin Chim Acta. 1985; 145: 341-8.
26. Raff etto JD, Khalil RA. Matrix metalloproteinases and their inhibitors in vascular remodeling and vascular disease. Biochem Pharmacol. 2008; 75 : 346-59.
27. Singhal A, Jayaraman M, Dhanasekaran DN, Kohli V. Molecular and serum markers in hepatocellular carcinoma: predictive tools for prognosis and recurrence. Crit Rev Oncol Hematol. 2012; 82 : 116-40.
28. Poon RT, Fan ST, Lo CM, Liu CL, Wong J. Intrahepatic recurrence aft er curative resection of hepatocellular carcinoma: long-term results of treatment and prognostic factors. Ann Surg. 1999; 229: 216-22.
29. Huang M, Liu G. The study of innate drug resistance of human hepatocellular carcinoma Bel7402 cell line. Cancer Lett. 1999; 135 : 97-105.
30. L lovet J M, R icci S, M azzaferro V, H ilgard P, G ane E, B lanc J F, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008; 359 : 378-90.
31. Worns MA, Weinmann A, Pfi ngst K, S chulte-Sasse C, M essow C M, Schulze-Bergkamen H, et al. Safety and effi cacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver cirrhosis. J Clin Gastroenterol. 2009; 43: 489-95.
32. Hao K, Luk JM, Lee NP, Mao M, Zhang C, Ferguson MD, et al. Predicting prognosis in hepatocellular carcinoma aft er curative surgery with common clinicopathologic parameters. BMC Cancer. 2009; 9: 389.
33. Korpi JT, Kervinen V, Maklin H, Vaananen A, Lahtinen M, Laara E, et al. Collagenase-2 (matrix metalloproteinase-8) plays a protective role in tongue cancer. Br J Cancer. 2008; 98: 766-75.
34. Kuula H, Salo T, Pirila E, Tuomainen AM, Jauhiainen M, Uitto VJ, et al. Local and systemic responses in matrix metalloproteinase 8-defi cient mice during Porphyromonas gingivalis-induced periodontitis. Infect Immun. 2009; 77 : 850-9.
35. McMillan SJ, Kearley J, Campbell JD, Zhu XW, Larbi KY, Shipley JM, et al. Matrix metalloproteinase-9 defi ciency results in enhanced allergen-induced airway infl ammation. J Immunol. 2004; 172: 2586-94.
36. Lopez-Otin C, Palavalli LH, Samuels Y. Protective roles of matrix metalloproteinases: from mouse models to human cancer. Cell Cycle. 2009; 8 : 3657-62.
37. McKenna GJ, Chen Y, Smith RM, Meneghetti A, Ong C, McMaster R, et al. A role for matrix metalloproteinases and tumor host interaction in hepatocellular carcinomas. Am J Surg. 2002; 183: 588-94.
38. Matsumoto E, Nakatsukasa H, Nouso K, Nakamura SI, Suzuki M, Kobayashi Y, et al. Elevated levels of tissue inhibitor of metalloproteinases (TIMPS) in human hepatocellular carcinomas. Comp Hepatol. 2004; 3(Suppl 1) : S51.
39. Okazaki I, Inagaki Y. Novel strategies for hepatocellular carcinoma based on MMPs science. Anti-cancer agents in medicinal chemistry. 2012; 12 : 753-63.
40. Arii S, Mise M, Harada T, Furutani M, Ishigami S, Niwano M, et al. Overexpression of matrix metalloproteinase 9 gene in hepatocellular carcinoma with invasive potential. Hepatology. 1996; 24: 316-22.
41. Miyoshi A, Kitajima Y, Sumi K, Sato K, Hagiwara A, Koga Y, et al. Snail and SIP1 increase cancer invasion by upregulating MMP family in hepatocellular carcinoma cells. Br J Cancer. 2004; 90: 1265-73.
42. Roeb E, Bosserhoff AK, Hamacher S, Jansen B, Dahmen J, Wagner S, et al. Enhanced migration of tissue inhibitor of metalloproteinase overexpressing hepatoma cells is attributed to gelatinases: relevance to intracellular signaling pathways. World J Gastroenterol. 2005; 11: 1096-104.
43. Z hang S, L i L, L in J Y, L in H. I mbalance between expression of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in invasiveness and metastasis of human gastric carcinoma. World J Gastroenterol. 2003; 9: 899-904.
44. H ayasaka A, S uzuki N, F ujimoto N, I wama S, F ukuyama E, K anda Y, et al. Elevated plasma levels of matrix metalloproteinase-9 (92-kd type IV collagenase/gelatinase B) in hepatocellular carcinoma. Hepatology. 1996; 24 : 1058-62.
45. S un M H, H an X C, J ia M K, J iang W D, W ang M, Z hang H, et al. E xpressions of inducible nitric oxide synthase and matrix metalloproteinase-9 and their eff ects on angiogenesis and progression of hepatocellular carcinoma. World J Gastroenterol. 2005; 11: 5931-7.
46. Nakatsukasa H, Ashida K, Higashi T, Ohguchi S, Tsuboi S, Hino N, et al. Cellular distribution of transcripts for tissue inhibitor of metalloproteinases 1 and 2 in human hepatocellular carcinomas. Hepatology. 1996; 24 : 82-8.
47. L ambert E, D asse E, H aye B, P etitfrere E. T IMPs as multifacial proteins. Crit Rev Oncol Hematol. 2004; 49: 187-98.
48. Puxbaum V, Mach L. Proteinases and their inhibitors in liver cancer. World J Hepatol. 2009; 1: 28-34.
49. Decock J, Hendrickx W, Vanleeuw U, Van Belle V, Van Huff el S, Christiaens MR, et al. Plasma MMP1 and MMP8 expression in breast cancer: protective role of MMP8 against lymph node metastasis. BMC Cancer. 2008; 8: 77.
50. Vayrynen JP, Vornanen J, Tervahartiala T, Sorsa T, Bloigu R, Salo T, et al. Serum MMP-8 levels increase in colorectal cancer and correlate with disease course and infl ammatory properties of primary tumors. Int J Cancer. 2012; 131: E463-74.
51. Vihinen P, Koskivuo I, Syrjanen K, Tervahartiala T, Sorsa T, Pyrhonen S. Serum matrix metalloproteinase-8 is associated with ulceration and vascular invasion of malignant melanoma. Melanoma Res. 2008; 18 : 268-73.
52. Dejonckheere E, Vandenbroucke RE, Libert C. Matrix metalloproteinase8 has a central role in infl ammatory disorders and cancer progression. Cytokine Growth Factor Rev. 2011; 22: 73-81.
53. Qiu W, Zhou G, Zhai Y, Zhang X, Xie W, Zhang H, et al. No association of MMP-7, MMP-8, and MMP-21 polymorphisms with the risk of hepatocellular carcinoma in a Chinese population. Cancer Epidemiol Biomarkers Prev. 2008; 17 : 2514-18.
54. Iredale JP, Benyon RC, Arthur MJ, Ferris WF, Alcolado R, Winwood PJ, et al. Tissue inhibitor of metalloproteinase-1 messenger RNA expression is enhanced relative to interstitial collagenase messenger RNA in experimental liver injury and fi brosis. Hepatology. 1996; 24: 176-84.
55. Knittel T, Mehde M, Kobold D, Saile B, Dinter C, Ramadori G. Expression patterns of matrix metalloproteinases and their inhibitors in parenchymal and non-parenchymal cells of rat liver: regulation by TNF-alpha and TGF-beta1. J Hepatol. 1999; 30: 48-60.
56. Watanabe T, Niioka M, Hozawa S, Kameyama K, Hayashi T, Arai M, et al. Gene expression of interstitial collagenase in both progressive and recovery phase of rat liver fi brosis induced by carbon tetrachloride. J Hepatol. 2000; 33: 224-35.
57. H emmann S, G raf J, R oderfeld M, R oeb E. E xpression of MMPs and TIMPs in liver fi brosis-a systematic review with special emphasis on anti-fi brotic strategies. J Hepatol. 2007; 46 : 955-75.
58. Kahari VM, Saarialho-Kere U. Matrix metalloproteinases and their inhibitors in tumour growth and invasion. Ann Med. 1999; 31: 34-45.
59. Saff roy R, Pham P, Reff as M, Takka M, Lemoine A, Debuire B. New perspectives and strategy research biomarkers for hepatocellular carcinoma. Clin Chem Lab Med. 2007; 45: 1169-79.